Mathai DS
Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas.
ArticlePsilocybin
Reported Safety Practices of Publicly Advertised Psychedelic Retreats.
ArticlePsilocybin
From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care.
ArticlePsilocybin
Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with obsessive-compulsive disorder: international findings from the LATINO Study.
ArticlePsychedelics
On Minimizing Risk and Harm in the Use of Psychedelics.
ArticlePsilocybin
Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use.
ArticlePsilocybin
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.
ArticleKetamine
Learning how to make use of dissociative therapies.
ArticleKetamine
At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.
ArticlePsilocybin
Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers.
PreprintPsilocybin
Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
PreprintPsilocybin
Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use
ArticlePsilocybin
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey.
ArticleKetamine
Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine.
ArticleKetamine
Toward Synergies of Ketamine and Psychotherapy.
ArticleKetamine